Beam Therapeutics (BEAM) Short term Debt (2025 - 2026)

Beam Therapeutics (BEAM) has reported Short term Debt for 2 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was $2.7 million, changed N/A from the prior year.
• Short term Debt held at $2.7 million in Q1 2026 per BEAM's latest filing, from $2.7 million in the prior quarter.
• Across five years, Short term Debt topped out at $2.7 million in Q4 2025 and bottomed at $1.2 million in Q3 2025.